Just like GFAP, NFL is a promising biomarker of neurodegeneration in MS [17, 47], dementia [48], TBI [38, 49], amyotrophic lateral sclerosis (ALS) and other neurological diseases [48, 50]. This evidence concerns the gene NEFL and myeloid sarcoma.